A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.
Hongfeng Gou(Sichuan University), Hu J(Sichuan University), Shuqin Ni(Shandong First Medical University), Pingan Yao(Soochow University), Junhua Zhang(Shanghai Advanced Research Institute), Bin Bai(First Hospital of China Medical University), Y Y Pan(Anhui Provincial Hospital), J. Ying(Zhejiang Cancer Hospital), Xiuying XIAO(Renji Hospital), H Li(Tianjin Medical University Cancer Institute and Hospital), X Lin(Fujian Medical University), Wei He(First Affiliated Hospital of Zhengzhou University), Li Zheng(Sichuan University), Han Cui(Jiangsu Hengrui Medicine (China)), Liwei Wang(Renji Hospital), Ling Lu(Xuzhou Medical College), Wenlong Zhai(Zhengzhou University), Wenhui Yang(Shanxi Provincial Cancer Hospital), 牛作兴(Shandong First Medical University)
Cited by 0
Related Papers
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652
miR396a-Mediated Basic Helix–Loop–Helix Transcription Factor bHLH74 Repression Acts as a Regulator for Root Growth in Arabidopsis Seedlings
|Plant and Cell Physiology|2014|142
NSUN2-Mediated mRNA m <b>5</b> C Modification Regulates the Progression of Hepatocellular Carcinoma
|Genomics Proteomics & Bioinformatics|2022|72
UIEDP: Boosting underwater image enhancement with diffusion prior
|Expert Systems with Applications|2024|65
Long Noncoding RNA AFAP1-AS1 Promoted Tumor Growth and Invasion in Cholangiocarcinoma
|Cellular Physiology and Biochemistry|2017|64